Fructose and liver function – is this behind nonalcoholic liver disease?

SummaryLittle is known about the regulation of high-molecular-weight-kininogen (HK) and low-molecular-weight-kininogen (LK) or the relationship of each to the degree of liver function impairment in patients with cirrhosis. In this study, we evaluated HK and LK quantitatively by a recently described particle concentration fluorescence immunoassay (PCFIA) and qualitatively by SDS PAGE and immunoblotting analyses in plasma from 33 patients with cirrhosis presenting various degrees of impairment of liver function. Thirty-three healthy subjects served as normal controls. Patients with cirrhosis had significantly lower plasma levels of HK (median 49 μg/ml [range 22-99 μg/ml]) and LK (58 μg/ml [15-100 μg/ml]) than normal subjects (HK 83 μg/ml [65-115 μg/ml]; LK 80 μg/ml [45-120 μg/ml]) (p < 0.0001). The plasma concentrations of HK and LK were directly related to plasma levels of cholinesterase (P < 0.0001) and albumin (P < 0.0001 and P < 0.001) and inversely to the Child-Pugh score (P < 0.0001) and to prothrombin time ratio (P < 0.0001) (reflecting the clinical and laboratory abnormalities in liver disease). Similar to normal individuals, in patients with cirrhosis, plasma HK and LK levels paralleled one another, suggesting that a coordinate regulation of those proteins persists in liver disease. SDS PAGE and immunoblotting analyses of kininogens in cirrhotic plasma showed a pattern similar to that observed in normal controls for LK (a single band at 66 kDa) with some lower molecular weight forms noted in cirrhotic plasma. A slight increase of cleavage of HK (a major band at 130 kDa and a faint but increased band at 107 kDa) was evident. The increased cleavage of HK was confirmed by the lower cleaved kininogen index (CKI), as compared to normal controls. These data suggest a defect in hepatic synthesis as well as increased destructive cleavage of both kininogens in plasma from patients with cirrhosis. The decrease of important regulatory proteins like kininogens may contribute to the imbalance in coagulation and fibrinolytic systems, which frequently occurs in cirrhotic patients.

Download Full-text

Urokinase Antigen in Plasma of Patients with Liver Cirrhosis and Hepatoma

Thrombosis and Haemostasis ◽

10.1055/s-0038-1660082 ◽

1985 ◽

Vol 54 (03) ◽

pp. 617-618 ◽

Cited By ~ 15

Author(s):

J C Kirchheimer ◽

K Huber ◽

P Polterauer ◽

B R Binder

Keyword(s):

Liver Cirrhosis ◽

Liver Disease ◽

Liver Function ◽

Matched Control ◽

Malignant Growth ◽

Control Groups ◽

Impaired Liver Function ◽

Impaired Liver ◽

Specific Medication ◽

History Of

SummaryPlasma urokinase antigen levels were studied in 78 patients suffering from liver diseases. Blood was drawn before any specific medication was initiated. Impairment of liver function was comparable in all patients. In both groups of cirrhotic liver disease (alcoholic and non-alcoholic), normal levels of plasma urokinase antigen were found as compared to age-matched control groups. In both groups of patients with hepatomas (with or without a history of liver cirrhosis), however, significantly increased plasma urokinase antigen levels could be determined. These data indicate that an increase in plasma urokinase antigen might rather relate to malignant growth in liver disease than to impaired liver function.

Download Full-text

Mechanisms of liver damage in COVID-19

Medical alphabet ◽

10.33667/2078-5631-2020-19-39-46 ◽

2020 ◽

Vol 1 (19) ◽

pp. 39-46

Author(s):

T. V. Pinchuk ◽

N. V. Orlova ◽

T. G. Suranova ◽

T. I. Bonkalo

Keyword(s):

Hepatocellular Carcinoma ◽

Liver Transplantation ◽

Risk Factor ◽

Liver Disease ◽

Liver Function ◽

Liver Damage ◽

The World ◽

Coronavirus Infection ◽

The Impact ◽

Analyze Data

At the end of 2019, a new coronavirus (SARS-CoV-2) was discovered in China, causing the coronavirus infection COVID-19. The ongoing COVID-19 pandemic poses a major challenge to health systems around the world. There is still little information on how infection affects liver function and the significance of pre-existing liver disease as a risk factor for infection and severe COVID-19. In addition, some drugs used to treat the new coronavirus infection are hepatotoxic. In this article, we analyze data on the impact of COVID-19 on liver function, as well as on the course and outcome of COVID-19 in patients with liver disease, including hepatocellular carcinoma, or those on immunosuppressive therapy after liver transplantation.

Download Full-text

Correlation between Liver function test, lipid profile fibroscan in non-alcoholic fatty liver disease

SVU-International Journal of Medical Sciences ◽

10.21608/svuijm.2020.48106.1024 ◽

2020 ◽

Vol 0 (0) ◽

pp. 0-0

Author(s):

Ali A. Ghweil ◽

Hassan S. Mahmoud ◽

Mohamed AbdelRazik El-senbesy ◽

Amal Shahat Mohammed

Keyword(s):

Liver Disease ◽

Liver Function ◽

Fatty Liver ◽

Lipid Profile ◽

Liver Function Test ◽

Fatty Liver Disease ◽

Alcoholic Fatty Liver ◽

Function Test ◽

Alcoholic Fatty Liver Disease

Download Full-text

Interventional Oncology Approach to Hepatic Metastases

Seminars in Interventional Radiology ◽

10.1055/s-0040-1719189 ◽

2020 ◽

Vol 37 (05) ◽

pp. 484-491

Author(s):

Cathal O'Leary ◽

Michael C. Soulen ◽

Susan Shamimi-Noori

Keyword(s):

Liver Disease ◽

Liver Function ◽

Interventional Oncology ◽

Hepatic Metastases ◽

Locoregional Therapy ◽

Treatment Modalities ◽

Patient Specific ◽

Curative Intent ◽

Locoregional Therapies ◽

Metastatic Liver

AbstractMetastatic liver disease is one of the major causes of cancer-related morbidity and mortality. Locoregional therapies offered by interventional oncologists alleviate cancer-related morbidity and in some cases improve survival. Locoregional therapies are often palliative in nature but occasionally can be used with curative intent. This review will discuss important factors to consider prior to palliative and curative intent treatment of metastatic liver disease with locoregional therapy. These factors include those specific to the tumor, liver function, liver reserve, differences between treatment modalities, and patient-specific considerations.

Download Full-text

Quantification of Liver Fat by MRI-PDFF Imaging in Patients with Suspected Non-alcoholic Fatty Liver Disease and Its Correlation with Metabolic Syndrome, Liver Function Test and Ultrasonography

Journal of Clinical and Experimental Hepatology ◽

10.1016/j.jceh.2020.11.004 ◽

2020 ◽

Author(s):

Gajanan A. Rodge ◽

Mahesh K. Goenka ◽

Usha Goenka ◽

Shivaraj Afzalpurkar ◽

Bhavik B. Shah

Keyword(s):

Metabolic Syndrome ◽

Liver Disease ◽

Liver Function ◽

Fatty Liver ◽

Liver Function Test ◽

Fatty Liver Disease ◽

Liver Fat ◽

Alcoholic Fatty Liver ◽

Function Test ◽

Alcoholic Fatty Liver Disease

Download Full-text

Editorial “Nutrition and Dietary Intake for Liver-Related Diseases”

Nutrients ◽

10.3390/nu13020390 ◽

2021 ◽

Vol 13 (2) ◽

pp. 390

Author(s):

Ewa Stachowska ◽

Karolina Jakubczyk ◽

Dominika Maciejewska-Markiewicz

Keyword(s):

Liver Disease ◽

Dietary Intake ◽

Special Issue ◽

Nonalcoholic Liver Disease

In this special issue, we focus on the role of nutrition in the therapy of nonalcoholic liver disease (NAFLD) [...]

Download Full-text

Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis

Diabetology & Metabolic Syndrome ◽

10.1186/s13098-021-00644-5 ◽

2021 ◽

Vol 13 (1) ◽

Author(s):

Sachiko Hattori ◽

Kazuomi Nomoto ◽

Tomohiko Suzuki ◽

Seishu Hayashi

Keyword(s):

Insulin Resistance ◽

Liver Disease ◽

Liver Function ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Hepatic Insulin Resistance ◽

Diabetic Patients ◽

Alcoholic Fatty Liver ◽

Dpp4 Inhibitor ◽

Alcoholic Fatty Liver Disease

Abstract Background Dipeptidyl peptidase 4 (DPP4) is a serine exopeptidase able to inactivate various oligopeptides, and also a hepatokine. Hepatocyte-specific overexpression of DPP4 is associated with hepatic insulin resistance and liver steatosis. Method We examined whether weekly DPP4 inhibitor omarigliptin (OMG) can improve liver function as well as levels of inflammation and insulin resistance in type 2 diabetic patients with non-alcoholic fatty liver disease (NAFLD). Further, we investigated the effects of OMG in a diabetic patient with biopsy-confirmed nonalcoholic steatohepatitis (NASH). Results In NAFLD patients, OMG significantly decreased levels of aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, homeostatic model assessment of insulin resistance (HOMA-IR), and high-sensitivity C-reactive protein (hsCRP), while no significant change was seen in hemoglobin A1c or body mass index. In the NASH patient, liver function improved markedly, and levels of the hepatic fibrosis marker FIB-4 decreased in parallel with HOMA-IR and hsCRP. Slight but clear improvements in intrahepatic fat deposition and fibrosis appeared to be seen on diagnostic ultrasonography. Conclusion Weekly administration of the DPP4 inhibitor OMG in ameliorating hepatic insulin resistance may cause beneficial effects in liver with NAFLD/NASH.

Download Full-text